Extracellular vesicles are mediators of intercellular communication with critical roles in cellular senescence and ageing. In arthritis, senescence is linked to the activation of a pro-inflammatory phenotype contributing to chronic arthritis pathogenesis. We hypothesised that senescent osteoarthritic synovial fibroblasts induce senescence and a pro-inflammatory phenotype in non-senescent osteoarthritic fibroblasts, mediated through extracellular vesicle cargo. Small RNA-sequencing and mass spectrometry proteomics were performed on extracellular vesicles isolated from the secretome of non-senescent and irradiation-induced senescent synovial fibroblasts. β-galactosidase staining confirmed senescence in SFs. RNA sequencing identified 17 differentially expressed miRNAs, 11 lncRNAs, 14 tRNAs and one snoRNA and, 21 differentially abundant proteins were identified by mass spectrometry. Bioinformatics analysis of miRNAs identified fibrosis, cell proliferation, autophagy, and cell cycle as significant pathways, tRNA analysis was enriched for signaling pathways including FGF, PI3K/AKT and MAPK, whilst protein analysis identified PAX3-FOXO1, MYC and TGFβ1 as enriched upstream regulators involved in senescence and cell cycle arrest. Finally, treatment of non-senescent synovial fibroblasts with senescent extracellular vesicles confirmed the bystander effect, inducing senescence in non-senescent cells potentially through down regulation of NF-κB and cAMP response element signaling pathways thus supporting our hypothesis. Understanding the exact composition of EV-derived small RNAs of senescent cells in this way will inform our understanding of their roles in inflammation, intercellular communication, and as active molecules in the senescence bystander effect.
Introduction

Senescence is a hallmark of ageing characterised by stable cell cycle arrest and secretion of pro-inflammatory molecules (Kumari and Jat, 2021). This complex senescence-associated secretory phenotype (SASP) can hinder tissue repair, regeneration, and function. The SASP consists of several soluble signalling factors which include pro-inflammatory cytokines (IL6, chemokines (IL8), matrix metalloproteinases (MMPs), growth factors and proteases. Senescent cells have dysregulated metabolism and mitochondrial function resulting in the release of DNA-damaging reactive oxygen species (ROS) also contributing to the SASP. Several studies found that senescent cells accumulate with age and in ageing tissue further promoting ageing and sustaining low level chronic inflammation (Da Silva et al., 2019; Kumari and Jat, 2021). Interestingly, the increasing number of senescent cells within joints correlates with the development of osteoarthritis (OA) (Coryell et al., 2021). OA affects up to 80% of older adults and globally, is the most common musculoskeletal joint condition characterised by cartilage degradation, subchondral bone remodelling and synovial inflammation known as synovitis (Jeon et al., 2018). Notably, chondrocytes, osteocytes and synovial fibroblasts, though not senescent, also produce pro-inflammatory SASP-associated factors and many SASP molecules induce OA-related joint changes (Coryell et al., 2021).

SASP producing senescent cells also contribute to the bystander effect, inducing senescent phenotypes in surrounding cells further facilitating joint degeneration (Nelson et al., 2018). The mechanisms by which senescent cells contribute to disease progression are not fully understood. Interestingly, extracellular vesicles (EVs), which have critical roles in mediating intercellular communication and are associated with cellular response, are being considered as part of the SASP. Secreted by all cell types, EVs are lipid membrane-bound sacs containing a variety of cell specific DNA, RNA and proteins (Pant et al., 2012). These nano-sized bio-vesicles are taken up by neighbouring or distant cells and studies show EV contents can reprogram recipient cells (Zhang et al., 2019). As such, cell type and state specific EVs are of immense biological interest, especially considering their role in disease pathology. Critically, it is important to understand the involvement of senescent cell derived EVs within the arthritic joint. EVs are highly prevalent in joint synovial fluid although whether specific cell types contribute to particular joint effects remains unknown as few studies have comprehensively profiled these EVs (Esa et al., 2019). Synovial fibroblasts (SFs) drive synovitis in the joint lining which mediates joint destruction. In vitro, studies show EVs from IL-1β stimulated synovial fibroblasts (SFs) can induce arthritic changes in articular chondrocytes (Kato et al., 2014). Interestingly, Del Rey et al., 2019 reported senescent SFs prematurely accumulated within the joint and accelerated senescence on inflammatory stimuli (Del Rey et al., 2019). These senescent SFs were linked to the activation of a pro-inflammatory phenotype contributing to SASP and chronic arthritis pathogenesis. As such we hypothesized that senescent SFs in osteoarthritis may induce senescence and a pro-inflammatory phenotype in non-senescent osteoarthritic SFs, mediated by senescent EV cargo.

In this study, we utilised both transcriptomic and proteomic approaches to identify differentially expressed small non-coding RNAs (sncRNAs) and differentially abundant proteins in senescent EVs as compared to non-senescent EVs. We demonstrated that senescent synovial fibroblasts can induce senescence in surrounding cells through the release of senescence associated EVs. Interestingly, we found treatment of OA SFs with senescent EVs dampened pro-inflammatory and ECM factors suggesting a transcriptional switch from arthritic SFs to senescent SFs.

Materials and methods

Cell culture and treatments

Joint tissue was collected peri-operatively from consenting OA patients following elective total joint replacement under ethical approval granted by UK National Research Ethics Committee (NRES 16/SS/0172). Synovial tissue prepared as previously described in RPMI 1640 supplemented with 10% FSC, 5% non-essential amino acids, 5% 1-glutamine, 5% sodium pyruvate and 1% penicillin/streptomycin (Sigma
A total of 2 µL total RNA were used as input for small RNA library preparation using the CleanTag Ligation Kit (Trilink, United States) and Illumina Index Primer Set1. Adapters were diluted 1:4 to account for low RNA input and reduce the formation of adapter dimers. Several PCR amplification cycles were tested to minimize primer and adapter dimer peaks as well as maximize the microRNA peak observed in the quality control using a Bioanalyzer DNA1000 high sensitivity chip (Agilent, United States). Ultimately, 26 PCR cycles were used. Barcoded libraries were again controlled using the Bioanalyzer DNA1000 high sensitivity chip and pooled at equimolar rate. The purified library was sequenced on a NovaSeq 6000 SP flow cell with 100bp single-end reads, aiming for 10–15 million reads per sample.

Data analysis was performed using the miND® pipeline (Khamina et al., 2022). Briefly, the overall quality of the next-generation sequencing data was evaluated automatically and manually with fastQC v0.11.8 (Andrews, 2010) and multiQC v1.7 (Ewels et al., 2016). Reads from all passing samples were adapter trimmed and quality filtered using cutadapt v2.3 (Martin, 2011) and filtered for a minimum length of 17 nt. Mapping steps were performed with bowtie v1.2.2 (Langmead et al., 2009) and miRDeep2 v2.0.1.2 (Friedlander et al., 2012), where reads were first mapped against the genomic reference GRCh38. p12 provided by Ensembl (Zerbino et al., 2018) allowing for two mismatches and subsequently mirbase v22.1 (Griffiths-Jones, 2004), filtered for miRNAs of hsa only, allowing for one mismatch. For a general RNA composition overview, non-miRNA mapped reads were mapped against RNAcentral (RNA Central, 2019) and then assigned to various RNA species of interest. Differential expression analysis with edgeR v3.28 (Robinson et al., 2010) was adapted for use with edgeR to remove low abundant miRNAs and thus optimize the false discovery rate (FDR) correction. Functional annotations and upstream regulator analysis of DEG was performed with Qiagen’s Ingenuity Pathway Analysis (IPA) software. All raw RNA sequencing data files can be found on NCBI’s GEO under accession GSE200330.

**Protein digestion**

Isolated EVs were supplemented with 25 mM ammonium bicarbonate (Fluka Chemicals Ltd., Gillingham, UK), containing 0.05% (w/v) RapiGest (Waters, Elstree, Hertfordshire, UK) to a final volume of 160 µL and heated at 80 °C for 10 min. DL-Dithiothreitol (Sigma-Aldrich) was subsequently added (1.2 mM final concentration) and incubated at 60°C for 10 min. Iodoacetamide (Sigma-Aldrich) was then added (3.6 mM final concentration) and incubated at 60°C for 10 min. Iodoacetamide (Sigma-Aldrich) was then added (3.6 mM final concentration) and incubated at 60°C for 10 min.
concentration), incubated in the dark at room temperature for 30 min and DL-dithiothreitol supplementation repeated for 10 min at room temperature. 2 μg of mass spectrometry grade trypsin/Lys-C (Promega, Southampton, UK) was added to each sample and rotated at 37 °C for 2 h. Trypsin/Lys-C supplementation was then repeated and samples rotated at 37°C for a further 16 h. Digests were then supplemented with trifluoroacetic acid (TFA, Sigma-Aldrich) to a 0.5% (v/v) final concentration, rotated at 37°C for 30 min and centrifuged at 13,000 g for 15 min at 4°C.

Liquid chromatography tandem mass Spectrometry and label-free quantification

Digests were subject to liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis using an Ultimate 3,000 Nanosystem (Dionex, Thermo Scientific) and Q-Exactive Quadrupole-Orbitrap instrument (Thermo Scientific) with settings as previously described (Thorpe et al., 2016). Proteins were identified using an in-house Mascot server (Matrix Science). Search parameters were as follows: enzyme, trypsin, peptide mass tolerances 10 ppm, fragment mass tolerance of 0.01 Da, 2+, and 3 + ions, with carbamidomethyl cysteine as a fixed modification and methionine oxidation as a variable modification, searching against the UniHuman Reviewed database, with a false discovery rate (FDR) of 1%, a minimum of two unique peptides per protein. Progenesis QI software (V4, Waters) was used to calculate fold changes (FC) in protein abundance. Proteins with p-value < 0.05 were considered differentially expressed (DE). All mass spectrometry raw files have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD032757 and 10.6019/PXD032757 (Perez-Riverol et al., 2019).

Construction of reporter plasmids, viral production, transduction and reporter gene assay

Binding sequences specific for transcription factors (i.e. NFκB-RE, CRE, API1, SRE, SRF-RE, SIE) extended with a minimal promoter sequence (AGAGGGTATATAATGGAAGCTCGACTTCCAG) were directionally cloned into the pNL1.2 vector (Promega). Subsequently, In-Fusing Cloning (TakaraBio) was used to generate lentiviral constructs by re-cloning the pNL1.2 reporters into the ClaI site of the pLVX-EF1α-IRES-Puro producer vector (TakaraBio) (Forward primer; AGATTCGATTATGGAAGCGTGCACCGT) (Reverse primer; ATGAATATATTACGCGCCCGGCACTTAAGATTGGCC). Viral supernatants generated in HEK293T cells (TakaraBio) using the fourth generation lentiviral production system (TakaraBio) were used to transduce (16 μg/ml DEAE-dextran, Sigma-Aldrich) SW1353 reporter lines. Following puromycin selection (2 μg/ml, Sigma-Aldrich), cells were trypsinized (Trypsin; ThermoFisher) and re-seeded (60,000 cells/cm²) into 384-well plates (Greiner Bio-One) and cultured overnight in DMEM/F12 supplemented with 0.5% FCS. Serum-starved cells were stimulated with 10% extracellular vesicles isolated from irradiated senescent (N = 7) or non-senescent control synovial fibroblasts (N = 7) (isolation details above) for 6 hours. After stimulation, cells were lysed using 15 μL Milli-Q. Following the addition of Nano-Glo reagent (1:1 ratio; Promega), luminescence was quantified using the Tristar2 LB942 multi-mode plate reader (Berthold Technologies).

Reporter gene assay

Stably expressing response element (i.e. NFκB-RE, CRE, API1, SRE, SRF-RE, SIE) driven Nano luciferase SW1353 (HTB-94, ATCC) reporter cell lines generated according to previously published protocol (Ripmeester et al., 2020). Reporter cells were trypsinized (Trypsin; ThermoFisher) and re-seeded (60,000 cells/cm²) into 384-well plates (Greiner Bio-One) and cultured overnight in DMEM/F12 supplemented with 0.5% FCS. Serum-starved cells were stimulated with 10% extracellular vesicles for 6 h. After stimulation, cells were lysed using 15 μL Milli-Q. Following the addition of Nano-Glo reagent (1:1 ratio; Promega), luminescence was quantified using the Tristar2 LB942 multi-mode plate reader (Berthold Technologies).

Statistics

Statistical analysis was performed using GraphPad Prism version 9. Data was analysed using students t-tests or ANOVAs with sample numbers as stated in figure legends.

Results

Senescence in synovial fibroblasts and extracellular vesicles

To investigate the pathogenesis of senescent EVs in arthritis, we established a primary cell senescence model using synovial fibroblasts isolated from osteoarthritis patients. Senescence associated β-galactosidase staining confirmed irradiation induced senescence in irradiated synovial fibroblasts compared to non-irradiated controls. Irradiated synovial fibroblasts were SA-β-galactosidase positive by 2-fold accounting for ~35% senescence of synovial fibroblasts compared to ~16.9% of non-irradiated control SFs and showed no morphological changes as a result of
irradiation (Figures 1A,B; Supplementary Data). To determine the effects on the inflammatory profile of these cells the levels of secreted IL-6 were measured by ELISA. Here, irradiated synovial fibroblasts showed no significant changes in the inflammatory secretory profile of these cells once results were adjusted for differences in cell numbers (Figure 1C). Cell counts showed a significant reduction in the number of irradiated synovial fibroblasts (Figure 1D). Counts did not decrease beyond number of cells plated for irradiation and no cellular debris was noticed on frequent observations suggesting irradiation may have resulted in cell cycle arrest as expected of senescent cells.

Once our model had been established, irradiated and non-irradiated control synovial fibroblasts were conditioned for an additional 3 days in serum-free culture media. Size exclusion chromatography was used to isolate EVs from conditioned media and EVs were characterised using mass spectrometry proteomics, nanoparticle tracking and electron microscopy (Figure 1E). The transmission electron microscopy tends to determine smaller particles than nanoparticle tracking and found a maxima peak mean for both groups of 46 nm with <20 nm standard deviation. Of note there were many particles in the 70–120 nm range. Nanoparticle tracking analysis found the average size of EVs remained unchanged between control EVs isolated from non-irradiated control SFs and senescent EVs isolated from irradiated SFs (224 ± 34 vs. 221.0 ± p = 0.85) (Figure 1F). Additionally, the number of EV particles produced by non-irradiated control SFs and irradiated SF showed a trend (7.7±3.6 × 109 vs. 12.4 ± 6.9 × 109; p = 0.13) of increased EV particles per cell in irradiated SFs, however this was not statistically significant (Figure 1G). In accordance with the minimal report guidelines (Thery et al., 2018), we investigated the abundance of three non-tissue specific EV transmembrane markers (CD81, CD9 and CD59) and two cytosolic proteins commonly recovered in EVs (Syntenin-1 and Annexin A1) to demonstrate the presence of EVs within our preparations. To determine the purity of our preparations, we sought to determine the abundance of ribosomal proteins 40S and 60S, which are reported to be major contaminating components that co-isolate with EVs. The data shows the presence of both EV transmembrane markers and EV cytosolic proteins in EV preparations from both control and senescent cells, whilst there is very low expression of ribosomal proteins 40S and 60S demonstrating the high degree of purity of the EV preparations (p < 0.0001) (Figure 1H).

Characterisation of senescent extracellular vesicle contents

Extracellular vesicles are carriers of proteins, lipids, and nucleic acids. As such, to determine the contents of control and irradiated EV cargo, isolated EVs underwent small RNA
transcriptomic and proteomic analysis. Small RNA-sequencing identified a variety of small non-coding RNAs (ncRNAs) which were similarly distributed between control and senescent EVs (Figure 2A). Small ncRNAs are considered a class of epigenetic modifying molecules which include micro- (miRNAs), transfer (tRNAs), ribosomal (rRNAs), small nuclear (snRNAs), small nucleolar (snoRNA) and piwi-interacting RNAs (piRNAs). Sequencing found tRNAs, rRNAs and miRNAs were the most abundant small ncRNAs within EVs making up ~11.4%, ~5.7 and ~1.5%, respectively, of transcripts in control EVs and ~11.6%, ~3.8 and ~1.6%, respectively of transcripts in senescent EVs (Figure 2A). There were no differences in number of reads between control and senescent EVs (p = 0.5831) (Figure 2A). Differentially gene expression (DEG) identified 17 miRNAs of interest, 12 down regulated and five upregulated in senescent-derived exosomes (p < 0.25) (Figures 1B,C; Supplementary Figure S2; Table 1). These included senescence, fibrosis and age-associated miRNAs upregulated in senescent EVs such as miR-483-5p (2.35 FC, p = 0.147), miR-486-5p (1.31 FC, p = 0.123), miR-126-3p (1.01 FC, p = 0.08) and downregulated in senescent EVs included miR-155-5p (1.83 FC, p = 0.027). Bioinformatic analysis of the 17 differentially expressed microRNAs using a ‘Core Analysis’ in Ingenuity Pathway Analysis (IPA) software identified fibrosis (p = 2.5E-6), cell proliferation (p = 6.8E-6), autophagy (p = 0.001) and cell cycle (p = 0.001) as significant functional pathways (Figure 2D). Network analysis predictions utilizing IPA database suggested miRNAs identified may inhibit cell proliferation (Figure 2E). To determine the potential targets of these miRNAs of interest miRNET analysis was performed which identified 116 mRNA targeted by the 17 miRNAs. These mRNAs included apoptotic mRNAs BBC3, BCL2, CDKN2A, FGFs, IGFs and TP53, extracellular matrix (ECM) factors ADAMT5S, CCN1, MMP13 and TIMP2, and inflammatory factors CD47, CSF1R, DPP4 and several ILs (IL1A, IL1B, IL32, IL33, IL6R) (Supplementary Table S2). Functional annotation of these mRNAs and miRNAs revealed pathways involved in senescence (p = 1.2 × 10-8), cellular stress (p = 1.4 × 10-7) and apoptosis (p = 1.1 × 10-7) and included the VEGF signalling...
pathway \((p = 3.8 \times 10^{-6})\) (Figure 2F). Interestingly, upstream regulator analysis identified TNF \((p = 2.34 \times 10^{-36})\), TGFB1 \((p = 9.02 \times 10^{-36})\) and IL-1B \((p = 2.39 \times 10^{-32})\) as known senescence and arthritis associated regulators of DEG miRNAs (Figure 2G).

DEG analysis also identified 11 lncRNAs, 13 tRNAs and one snRNA differentially expressed (Figure 3A; Table 2). The tRNAs were of particular interest as tRNA derived small ncRNAs are thought to have miRNA-like regulatory capabilities and as such may be novel entities for therapeutic targeting (Shigematsu and Kirino, 2015). The sequences of DEG tRNAs were annotated using the transfer RNA related Fragment database (tRFDB) and two were identified, tRNA-Gly-GCC (URS00005AFD62) and tRNA-Gly-GCC (URS00006CF521), with tRFIDs 5004c and 5003c (Figure 3B). Using these known tRFIDs, tRF Target database was used to generate a list of potential targets of these tRNAs with energy scores predicting the likelihood of these tRNAs acting as miRNAs. A total of 1,534 targets were identified for 5003c and 1,532 targets were identified for 5004c. Due to the sequence similarity of these two tRNAs we sought to identify overlapping targets and report 594 miRNAs targeted by both tRNAs (Figure 3C; Supplementary Table S3). These targets were functionally characterised by Reactome Pathway prediction tool to be involved in FGF signalling \((p = 3.4 \times 10^{-6})\), PI3K/AKT signalling \((p = 1.0 \times 10^{-5})\) and MAPK pathways \((p = 3.1 \times 10^{-4})\) (Figure 3D).

Isolated EVs were further analysed by mass spectrometry proteomics analysis and label-free quantification undertaken. This revealed 21 differentially abundant proteins, of which 20 were downregulated and one was increased in senescent EVs. These included CSE1L \((-2.45\) FC, \(p = 0.03)\), GCNT1 \((-191.6\) FC, \(p = 0.05)\), PDG \((-7.8\) FC, \(p = 0.03)\) and NPTX1 \((-6.3\) FC, \(p = 0.009)\) which were significantly up or down regulated in senescent EVs (Figure 4A; Table 3). Functional Enrichment analysis (FunRich) confirmed many of the proteins identified were extracellular (60%, \(p = 0.001)\) or exosome components (55%, \(p = 0.016)\) (Figure 4B). Additionally, upstream regulator (USR) analysis of the 21 differentially abundant proteins using IPA identified PAX3-FOXO1, MYC, TGFB1 and TP53 all involved in senescence and cell cycle arrest as upstream regulators of altered EV proteins (Figure 4C). Network analysis predictions using IPA found activation of PAX3-FOXO1 (\(p = 1.2 \times 10^{-4}\),
z-score = 2) and MYC (p = 7.5 × 10^{-4}, z-score = 0.8) and inhibition of anti-inflammatory TGFB1 (p = 6.1 × 10^{-4}, z-score = -1.2) (Figure 4D).

**Senescent extracellular vesicles and the bystander effect**

Finally, to establish whether EVs alone could induce senescence in non-senescent synovial fibroblasts, cells were treated with purified control and senescent EVs. Non-senescent synovial fibroblasts were treated with 10^7 EV particles over 14 days and senescence was determined with SA-β-galactosidase staining. Treatment with senescent EVs alone resulted in over a three-fold and two-fold increase on day 3 and day 9, respectively, confirmed by SA-β-galactosidase staining (D3: 23.7 ± 9.2 vs. 6.6 ± 2.5, p < 0.0001, D9: 63.8 ± 18.9 vs. 29.3 ± 7.64) (Figure 5A). Prolonged exposure to senescent EV reduced fibroblast cell number which SA-β-galactosidase staining was adjusted for, although no significant changes were detected in IL-6 secretion (Figure 5B; Supplementary Figure S3). Interestingly, RT-PCR analysis found that senescent EVs dampened the inflammatory phenotype of arthritic synovial fibroblasts in the first 3 days of treatment resulting in downregulation of IL-6, IL-8 and IL-1β, and matric remodelling factors MMP1, MMP3, ADAM10, ADAM12, COL1A1, and COL1A2 (Figure 5C). No significant effects were noted in senescence and cell cycle markers p16, p21 and p53 at day 3 or day 9, however p53 was significantly induced in senescent EV treated cells at 4h (Figure 5C; Supplementary Figure S4). Whilst prolonged exposure to senescent EVs (9 days) significantly increased expression of inflammatory OA and senescence associated markers including MMP3, ADAM10, ADAM12, COL1A1 and COL1A2. (Figure 5C). No significant effects were noted in senescent control EVs compared to non-senescent control EVs.

| RNA Type | Gene Reference | Log (Fold Change) | p-value |
|----------|----------------|-------------------|---------|
| lncRNA   | Homo sapiens (human) non-protein coding lnc-JPH3-2:1 | -9.16986 | 0.000363 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-OSMR-2:1 | 6.970119 | 0.00103 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-SHANK1-1:1 | -7.16186 | 0.005861 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-ERMARD-2:1 | -6.84115 | 0.012497 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-CAGE1-1:5-1 | -6.44395 | 0.018785 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-CHORFI35-2:2 | 4.207866 | 0.020931 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-RAB9B-2:1 | -6.35022 | 0.02106 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-RAI2-2:1 | 6.041448 | 0.02992 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-SFMBT1-5:1 | 5.984509 | 0.032055 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-ADGRF3-3:1 | -5.94978 | 0.034132 |
| lncRNA   | Homo sapiens (human) non-protein coding lnc-METTL2B-3:7 | 4.738157 | 0.038856 |
| tRNA     | Homo sapiens transfer RNA-Val (AAC) 4-1 (TRV-AAC4-1) | 5.39902 | 0.007755 |
| tRNA     | Homo sapiens transfer RNA-Glu (TTC) 3-1 (TRE-TTC3-1) | 4.978853 | 0.001346 |
| tRNA     | Homo sapiens transfer RNA-Val (CAC) 5-1 (TRV-CAC5-1) | -4.73597 | 0.001869 |
| tRNA     | Homo sapiens (human) tRNA-Lys | -4.90269 | 0.002975 |
| tRNA     | tRNA3Lys from Homo sapiens (PDB 5CD1, chain M) | -4.39315 | 0.005317 |
| tRNA     | Homo sapiens transfer RNA-Ala (AGC) 2-1 (TRA-AGC2-1, TRA-AGC2-2, TRA-AGC7-1) | 5.65347 | 0.007501 |
| tRNA     | Homo sapiens transfer RNA-Lys (TIT) 5-1 (TRK-TTTS5-1) | 3.728341 | 0.011775 |
| tRNA     | Homo sapiens transfer RNA-Glu (TTC) 4-1 (TRE-TTC4-1, TRE-TTC4-2) | 3.6769 | 0.013233 |
| tRNA     | Homo sapiens transfer RNA-Ala (CCG) 4-1 (TRA-CCG4-1) | 4.048057 | 0.016099 |
| tRNA     | Homo sapiens (human) transfer RNA-Glu | -3.29739 | 0.021338 |
| tRNA     | Homo sapiens tRNA | -3.33278 | 0.021851 |
| tRNA     | Homo sapiens transfer RNA-Cys (GCA) 2-1 (TRC-GCA2 1-4) | -3.80403 | 0.033819 |
| tRNA     | Homo sapiens tRNA Gly GCC | -3.23536 | 0.039213 |
| snoRNA   | Homo sapiens (human) small nuclear RNA, C/D box 33 (SNORD33) | 1.341 | 0.2766 |

z-score = 2) and MYC (p = 7.5 × 10^{-4}, z-score = 0.8) and inhibition of anti-inflammatory TGFB1 (p = 6.1 × 10^{-4}, z-score = -1.2) (Figure 4D).
reporter cell lines suggesting these two pathways are key in the regulatory effects of senescent EV contents (Figure 5D).

**Discussion**

SASP producing senescent cells accumulate with age and their increase correlates with incidence of osteoarthritis. Additionally, several SASP factors overlap in both senescence associated tissue damage and osteoarthritis and as such it is important to understand the association of senescence and degenerative joint conditions. In this study we have profiled extracellular vesicles as part of the SASP response of senescent cells and utilised small non-coding RNA transcriptomic and mass spectrometry proteomic approaches to characterise EV contents. We isolated senescent EVs, whose cargo included a catalogue of miRNAs, tRNAs and proteins, which were able to induce senescence in non-senescent synovial fibroblasts, confirming the bystander effect and suppressing pro-inflammatory factors in arthritic synovial fibroblasts. Finally, we found that the contents of senescent EVs likely influence cellular senescence and inflammation potentially through the downregulation of the CRE and NF-κB signalling pathways.

Characterising senescent EVs from human synovial joint fibroblasts in this way has identified several miRNAs and tRNAs of interest for further investigation.

Regulation of senescence and arthritic joint inflammation consists of many overlapping regulatory molecules and phenotypes; thus, it is important to understand the specific molecular differences that favour progression of senescence or arthritic inflammation. Here, we have identified several miRNAs in EVs isolated from human synovial fibroblasts which are known to be involved in senescence, fibrosis and ageing as well as osteoarthritis. These included miR-483-5p (Chouri et al., 2018; Shen et al., 2020), miR-486-5p (Faraonio et al., 2012; Kim et al., 2012), miR-127-3p (Auler et al., 2021), miR-126-3p (Alique et al., 2019) and miR-155-5p (Bonifacio and Jarstfer, 2010; Faraonio et al., 2012; Wang B. et al., 2020). In human adipose-derived mesenchymal stem cells (hADSCs), miR-483 expression was upregulated during subsequent passages which correlated with adipogenesis and senescence (Shen et al., 2020). Both the adipogenic and senescence potential of hADSCs was reduced on silencing of miR-483 which was found to target insulin-like growth factor-1 (IGF1). Similarly, this miRNA is upregulated in articular cartilage of OA patients and lentiviral overexpression of miR-483 in transgenic mice resulted in higher incidence of age-related OA, whilst antagonir silencing delayed
A circulating miRNA identified as a biomarker for diagnosis and severity of knee OA (Kong et al., 2017), miR-486, was also found to induce senescence through double-stranded DNA damage and ROS accumulation in human diploid fibroblasts (Faraonio et al., 2012). Additionally, miR-127, in exosomes from bone marrow-derived mesenchymal stem cells, was reportedly protective against IL-1B-induced chondrocyte damage through inhibition of the Wnt/B-catenin pathway (Dong et al., 2021). Here in our study, we identified miR-127 as upregulated in senescent EVs which may be responsible for the downregulation of pro-inflammatory cytokines and ECM components. Conversely, during wound healing, miR-127 was reported to promote cell proliferation and ECM deposition.

| Accession | Description | Peptide Count | Unique Peptides | Anova (p-value) | Max Fold Change | Highest Mean Condition | Lowest Mean Condition |
|-----------|-------------|---------------|----------------|-----------------|------------------|------------------------|-----------------------|
| P20774    | Memecon OS = Homo sapiens | 10 | 9  | 2.7 | control | senescence |
| Q15818    | Neuronal pentraxin-1 OS = Homo sapiens | 6 | 6  | 0.01 | 6.3 | control | senescence |
| Q9NZT1    | Calmodulin-like protein 5 OS = Homo sapiens | 3 | 3  | 0.02 | 2.2 | control | senescence |
| P60174    | Triosephosphate isomerase OS = Homo sapiens | 4 | 4  | 0.02 | 3  | control | senescence |
| Q99715    | Collagen alpha-1 (XII) chain OS = Homo sapiens | 89 | 85 | 2.7 | control | senescence |
| Q9C0C2    | 182 kDa tankyrase-1-binding protein OS = Homo sapiens | 2 | 2  | 4.3 | control | senescence |
| P35527    | Keratin, type I cytoskeletal 9 OS = Homo sapiens | 38 | 36 | 1.9 | control | senescence |
| P52209    | 6-phosphogluconate dehydrogenase, decarboxylating OS = Homo sapiens | 3 | 3  | 7.8 | control | senescence |
| Q9HCU3    | Endosialin OS = Homo sapiens | 10 | 10 | 2.1 | control | senescence |
| P55060    | Exportin-2 OS = Homo sapiens | 1 | 1  | 2.4 | senescence | control |
| P13647    | Keratin, type II cytoskeletal 5 OS = Homo sapiens | 32 | 18 | 2.3 | control | senescence |
| P16035    | Metalloprotease inhibitor 2 OS = Homo sapiens | 11 | 9  | 4.5 | control | senescence |
| Q9F2B2    | Prostaglandin F2 receptor negative regulator OS = Homo sapiens | 21 | 20 | 2  | control | senescence |
| P35442    | Thrombospondin-2 OS = Homo sapiens | 43 | 36 | 1.7 | control | senescence |
| P06865    | Beta-hexosaminidase subunit alpha OS = Homo sapiens | 5 | 4  | 3.6 | control | senescence |
| Q12841    | Follistatin-related protein 1 OS = Homo sapiens | 11 | 11 | 1.4 | control | senescence |
| P09497    | Clathrin light chain B OS = Homo sapiens | 1 | 1  | 3.1 | control | senescence |
| Q8N129    | Protein canopy homolog 4 OS = Homo sapiens | 5 | 5  | 3.4 | control | senescence |
| Q02742    | Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylgalactosaminyltransferase OS = Homo sapiens | 1 | 1  | 191.6 | control | senescence |
| Q92743    | Serine protease HTRA1 OS = Homo sapiens | 16 | 16 | 2.5 | control | senescence |
| Q4HB40    | Retinoid-inducible serine carboxypeptidase OS = Homo sapiens | 6 | 6  | 4  | control | senescence |
induced prolonged cell cycle arrest and activating SA-b galactosidase in dermal fibroblasts also similar to effects we report here (Auler et al., 2021). These miRNAs are highly abundant in our EVs isolated from senescent cells and treatment with senescent EVs induced senescence in control fibroblasts suggesting EVs carry an imprinted signature from their parent cells and are able to transfer this imprint to other cells. This imprint is likely to be these DE miRNAs which can epigenetically regulate senescence induction in non-senescent cells. Furthermore, these miRNA-containing senescent EVs initially suppressed pro-inflammatory cytokines in non-senescent OA fibroblasts and on prolonged treatment we observed upregulation across all markers suggesting a switch in fibroblast phenotype from being pro-inflammatory arthritic fibroblasts to senescent fibroblasts. This may be attributed to the trend we observed of downregulated CRE and NF-κβ signalling pathways which are integral regulators of pro-inflammatory cytokines. Studies report increased pro-inflammatory factors as a result of senescence which we only observe at day 9 of treatment, however our study utilised OA synovial fibroblasts which are phenotypically inflammatory to start with and as such the influence of senescent EVs in this context appears to initially suppress joint degenerative factors including interleukins, matrix metalloproteases and ECM components. It will be of huge clinical

**FIGURE 5**

Isolated senescent EVs can induce bystander effect in non-senescent cells. (A) Percentage of senescence-associated β-galactosidase staining of senescent EV treated synovial fibroblasts over 14 days. N = 4. (black asterisks: RMPI Control vs. Senescent EV, red asterisks: EV depleted RMPI vs. Senescent EV, blue asterisks: Control EV vs. Senescent EV). (B) Senescence associated secretory phenotype (SASP) determined by IL-6 ELISA at day 5 and day 9 of EV treatment (N = 6). (C,D) SASP and senescent EV associated genes of interest quantified by RT-PCR (N = 6). (E) Reporter assay for key signalling pathways using SW1355 reporter cells following treatment with control and senescent EVs. Error bars represent standard error of the mean. Statistical analysis include repeated measures ANOVA (A) and paired student’s t-test (C–E). *p < 0.05, **p < 0.01, ***p < 0.001.
relevance to establish which of the EV miRNAs identified are responsible for driving these two differing phenotypes.

Similarly, tRNAs are increasingly becoming of interest given their potential to act in a miRNA-like manner (Shigematsu and Kirino, 2015). We found predicted tRNA targets were enriched for proteins regulating FGF, PI3K/AKT and MAPK pathways which are upstream of the NF-kB pathway, a pathway we determined to be suppressed by senescent EVs in our reporter assays. Additionally, we identified several differentially abundant proteins of interest in our senescent EVs. CSE1L, also known as CAS (cellular apoptosis susceptibility protein), is an EV membrane protein which was highly abundant in senescent EVs (Jiang, 2016). CAS is involved in microvesicle formation, nucleocytoplasmic transport, chromatin binding and regulates expression of p53 target genes (Tanaka et al., 2007; Jiang, 2016). Meanwhile, the pro-inflammatory and senescence associated GCNT1, PDG and NPTXI were significantly reduced in senescent EVs. GCNT1 encodes an enzyme critical for memory t-cell response and lymphocyte trafficking suggesting a dampening of pro-inflammatory stimuli by senescent EVs (Wolf et al., 2021). PDG is an integral competent of the pentose phosphate pathway, depletion of which results in senescence due to the accumulation of p53 whilst NPTXI is involved in mitochondrial dysfunction (Sukhatme and Chan, 2012; Guzeloglu-Kayisli et al., 2014; Wang Z. et al., 2020). Exploring the involvement of miRNAs, tRNAs and proteins identified in senescent EVs and how they impact key signaling events within joint cells will better inform our understanding of how senescence and joint inflammation overlap and differ. Indeed future work will endeavor to validate these identified targets and establish their functional roles utilizing silencing and rescue experiments.

Canonical pathway analysis revealed many of the DE miRNAs, tRNAs and proteins had similar functions involved in senescence, cell stress and apoptosis suggesting these factors are co-expressed and as such are regulated by the same master regulators. An alternative approach to targeting miRNAs, tRNAs and proteins individually would be to target the relevant upstream regulators. Our bioinformatics analysis identified TNF, TGFβ1 and IL-1B as upstream regulators of the DE miRNAs. Interestingly, long-term exposure to TNF results in p38-MAPK and ROS-mediated premature senescence of human skin fibroblasts where TNF-a is induced as a result of UV exposure and chronic wound healing. Proliferation was reduced in these dermal fibroblasts whilst senescence associated β-galactosidase staining was increased similar to our findings. Whilst in oncogene-induced senescence, targeting of IL-1 established this pathway was necessary for SASP expression but not for senescence associated cell cycle exit (Lau et al., 2019). Although several anti-IL-1 therapeutics exist there are still populations of OA patients that show no clinical changes and recent trials describe negative results in vivo even though there are strong clinically relevant responses in vitro (Chevalier and Eymard, 2019). One aspect not considered by such studies is the effect of senescence-associated cell cycle exit versus the IL-1 induced inflammatory response that overlaps with SASP. As such targeting IL-1 alone may not be enough to circumvent the effects of senescent cells that accumulate in arthritic joints. Instead establishing the phases at which cell cycle arrest occurs and targeting factors involved at these checkpoints along with IL-1 could prove more successful. The TGFβ1 upstream regulator was also identified in our proteomics analysis suggesting this could be a broader target of interest. TGFβ1 is well established as a regulator of cellular senescence due to its Smad3 dependent transcriptional regulation of cell-cycle inhibitors p21 and p15INK4B (Zhang et al., 2017). Our proteomics analysis also identified the onco-fusion protein POX3-FOXO1 as an enriched upstream regulator of senescent EVs proteins. Interestingly PAX3-FOXO1 is known to regulate miR-486-5p, a miRNA enriched in our senescent EVs, thought to contribute to the pathogenesis of alveolar rhabdomyosarcoma resulting in increased proliferation and invasion (Hanna et al., 2018). Although silencing of PAX3-FOXO1 in this study reduced cell doubling potential to the point of inducing senescence and apoptosis. Additionally, studies show PAX3-FOXO1 reduces p16 INK4B bypassing senescence checkpoints (Linardic et al., 2007), which in turn regulates MYC and TP53, both identified in our USR analysis and involved in cell cycle arrest (Haas et al., 1997). Although, we did not find significant differences in cell cycle arrest markers by qPCR, these markers are notably transient and so the effects may not have been detected at the transcriptional level. Few studies have explored the effects of PAX3-FOXO1 outside of cancer and as such much remains to be determined on the involvement of PAX3-FOXO1 in joint conditions which may be of significant interest for therapeutic targeting.

As with many studies, the observations reported here should be considered in the light of some limitations. It is important to note that the UV induced senescence model used here is not representative of the multiple internal and external stressors which contribute to cellular senescence within the joint. Additionally, the study utilized primary synovial fibroblasts isolated from tissues from a small sample size of OA patients which may not be representative of the population. Furthermore, natural variation between patients contributed to heterogeneity in EV miRNA sequencing and protein mass spectrometry data. As such the significance threshold was reduced to p < 0.25 in order to identify miRNAs of relevance. Our retrospective analysis found all the identified miRNAs were previously linked to senescence, inflammation and/or osteoarthritis which was further supported by IPA bioinformatics analysis, although it is important for future studies to confirm the presence of these miRNAs from EVs within the arthritic joint with respect to senescence fibroblast populations. Lastly, signalling pathways identified by reporter assays require robust validation within synovial fibroblasts.
In conclusion, this study has systematically characterised the contents of senescent EVs and identified several miRNAs, tRNAs and proteins of interest. We have gone further to computationally analyse each of these components and found several common regulators of interest. Additionally, we have established that these EVs are capable of inducing senescence in healthy cells and that too potentially through the regulation of NK-κβ and CRE signalling pathways. Going forward it is necessary to establish the functional significance and mechanisms of each of the identified components of senescent EVs. Certainly, the EV cargo and the upstream regulators identified here will serve as potential therapeutic targets in future studies.

Data availability statement

The datasets generated for this study can be found in the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD032757 and 10.6019/PXD032757 and on NCBI’s Gene Expression Omnibus with the accession number GSE200330.

Ethics statement

The studies involving human participants were reviewed and approved by the UK National Research Ethics Committee (NRES 16/SS/0172). The patients/participants provided their written informed consent to participate in this study.

Author contributions

MP, VJ, and SJ designed the study. SW, JA, TB, DN, BH, JG, MH, VJ, KC, KA, and TW carried out experiments and data analysis. SW wrote the manuscript. SW, MP, VJ, and SJ carried out data interpretation and edited the manuscript. All authors edited and approved the final manuscript.

Funding

Mandy Peffers is funded through a Wellcome Trust Intermediate Clinical Fellowship (107471/Z/15/Z). James Anderson’s postdoctoral position is funded through a Horserace Betting Levy Board Research Project Grant (T15), Susanne Wijesinghe and Dominika Nanus’ postdoctoral positions are funded by Versus Arthritis, UK (21530; 21812). Victoria James, Kenton P Arkill, Thomas J Brown and Katie K Choi are funded by the Biotechnology and Biological Sciences Research Council (grant number BB/T008369/1). Our work was supported by the Medical Research Council (MRC) and Versus Arthritis as part of the MRC Versus Arthritis Centre for Integrated research into Musculoskeletal Ageing (CIMA) and MRC Versus Arthritis Centre for Musculoskeletal Ageing Research (CMAR).

Acknowledgments

The authors acknowledge all study participants, research staff at The Royal Orthopaedic Hospital NHS Foundation Trust and Russell’s Hall Hospital, Dudley for obtaining consents and screening. We also thank Dr Julie Watts and the staff at the Nanoscale and Microscale Research Centre.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2022.971621/full#supplementary-material

References

Alique, M., Bodega, G., Giannarelli, C., Carrascosa, J., and Ramírez, R. (2019). MicroRNA-126 regulates Hypoxia-Inducible Factor-1α which inhibited migration, proliferation, and angiogenesis in replicative endothelial senescence. Sci. Rep. 9, 7381. doi:10.1038/s41598-019-43689-3

Andrews, S. (2010). Babraham bioinformatics—FastQC a quality control tool for high throughput sequence data. [Online]. Available: https://www.bioinformatics.babraham.ac.uk/projects/fastqc/.

Auler, M., Bergmeier, V., Georgieva, V. S., Pitáier, L., Frie, C., Nuchel, J., et al. (2021). miR-127-3p is an epigenetic activator of myofibroblast senescence situated in...
within the MicroRNA-enriched dkl-1-Dio3Imprinted domain on mouse chromosome 12. J. Invest. Dermatol. 141, 1076–1086 e3. doi:10.1016/j.jid.2020.11.011

Bonifaci, L. N., and Jarstfer, M. B. (2010). MiRNA profile associated with replicative senescence, extended cell culture, and ectopic telomerase expression in human foreskin fibroblasts. PLoS One 5, e12519. doi:10.1371/journal.pone.0012519

Chevalier, E., and Eymard, F. (2019). Anti-IL-1 for the treatment of OA: Dead or alive? Nat. Rev. Rheumatol. 15, 191–192. doi:10.1038/s41581-018-0185-y

Chou, E., Servaes, N. H., Bekker, C. P. J., Afandji, A. J., Cossu, M., Hillen, M. R., et al. (2018). Serum microRNA screening and functional studies reveal miR-483-5p as a potential driver of fibrosis in systemic sclerosis. J. Autoimmun. 90, 162–168. doi:10.1016/j.jaut.2017.12.015

Coryell, P. R., Diekman, B. O., and Loeser, R. F. (2021). Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat. Rev. Rheumatol. 17, 47–57. doi:10.1038/s41586-020-00533-7

Da Silva, P. F. L., Ogorodnik, M., Kucheryavenko, O., Gilbert, J., Miwa, S., Cameron, K., et al. (2019). The bystander effect contributes to the accumulation of senescent cells in vivo. Aging Cell 18, e12848. doi:10.1111/acel.12848

Del Rey, M. J., Vallin, A., Usategi, A., Ergueta, S., Martin, E., Municio, C., et al. (2019). Senescent synovial fibroblasts accumulate prematurely in rheumatoid arthritis tissues and display an enhanced inflammatory phenotype. Immun. Ageing 16, 29. doi:10.1186/s12979-019-0161-9

Dong, J., Li, L., Fang, X., and Zang, M. (2021). Exosome-encapsulated microRNA 127-3p released from bone marrow-derived mesenchymal stem cells alleviates vesicles in the synovial joint: Is there a role in the pathophysiology of osteoarthritis? Res. Aging Immun. 89, 162–174. doi:10.1016/j.jaut.2017.12.015

Lau, L., Porcincula, A., Yu, A., Iwakura, Y., and David, G. (2019). Uncoupling the senescence-associated secretory phenotype from cell cycle exit via interleukin-1 modulation unveils its putative role in vivo. Mol. Cell. Biol. 39, e01588-18. doi:10.1128/MCB.01588-18

Leduc, C. D., Naini, S., Herndon, J. E., Nd, Kesserwan, C., Qualman, S. J., and Counter, C. M. (2017). The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 77, 6691–6699. doi:10.1158/0008-5472.CAN-16-3210

Love, M. I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. doi:10.1186/s13059-014-0360-8

Martin, M. (2011). Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBR J. 17, 10–12. doi:10.1093/embnet/jqt021

Nanus, D. E., Badoume, A., Wijesinghe, S. N., Hasley, A. M., Hurley, P., Ahmed, Z., et al. (2021). Synovial tissue from sites of joint pain in knee osteoarthritis patients exhibits a differential phenotype with distinct fibroblast subsets. EBioMedicine 72, 103618. doi:10.1016/j.ebiom.2021.103618

Nanus, D. E., Wijesinghe, S. N., Pearson, M. J., Hadjicharalambous, M. R., Rosser, A., Davs, E. T., et al. (2020). Regulation of the inflammatory synovial fibroblast phenotype by metastasis-associated lung adenocarcinoma transcript 1 long noncoding RNA in obese patients with osteoarthritis. Arthritis Rheumatol. 72, 609–619. doi:10.1002/art.41158

Nelson, G., Kucheryavenko, O., Wordsworth, J., and Von Zglinicki, T. (2018). The senescent bystander effect is caused by ROS-activated NF-κB signalling. Mech. Ageing Dev. 170, 30–36. doi:10.1016/j.maded.2017.08.005

Pant, S., Hilton, H., and Burczynski, M. E. (2012). The multifaceted exosome: Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem. Pharmacol. 83, 1484–1494. doi:10.1016/j.bcp.2011.12.037

Perez-Riverol, Y., Cordas, A., Bai, J., Bernal-Llanares, M., Hewapatirana, S., Kundu, D. J., et al. (2019). The PRIDE database and related tools and resources in 2019: Improving support for quantification data. Nucleic Acids Res. 47, D442–D450. doi:10.1093/nkx110

Ripmeester, E. G. J., Caron, M. M. J., Van Der Akker, G. H. G., Surtel, D. A. M., Cremers, A., Balaskas, P., et al. (2020). Impaired chondrocyte UC snoRNA expression in osteoarthritis impacts the chondrocyte protein translation apparatus. Sci. Rep. 10, 13426. doi:10.1038/s41598-020-70453-9

Robertson, M. D., McCarthy, D. J., and Smyth, G. K. (2010). edgex: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140. doi:10.1093/bioinformatics/btp146

Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., et al. (2012). Fiji: An open-source platform for biological-image analysis. Nat. Methods 9, 676–682. doi:10.1038/nmeth.1909

Shen, J., Zhu, X., and Liu, H. (2020). MiR-483 induces senescence of human adipose-derived mesenchymal stem cells through IFI1G inhibition. Aging (Albany NY) 12, 15756–15776. doi:10.18632/aging.103810

Shigematsu, M., and Kiritani, Y. (2015). tRNA-derived short non-coding RNA as interacting partners of argonaute proteins. Gene Regul. Syst. Bio. 9, 27–33. doi:10.1186/s13092-015-0141-7

Sukhatme, V. P., and Chan, B. (2012). Glycogenic cancer cells lacking 6-phosphogluconate dehydrogenase metabolize glucose to induce senescence. FEBS Lett. 586, 2389–2395. doi:10.1016/j.febslet.2012.05.052

Tanaka, T., Ohkubo, S., Tatsuori, S., and Prives, C. (2007). hCAS/CSE1 associates with chromatin and regulates expression of p53 target genes. Cell 130, 638–650. doi:10.1016/j.cell.2007.08.001

RNA Central (2019). RNAcentral: A hub of information for non-coding RNA sequences. Nucleic Acids Res. 47, D1230–D1231. doi:10.1093/nar/gkx1206

Thery, C., Witwer, K. W., Aikawa, E., Alcara, M. J., Anderson, J. D., Andriansahitohaina, R., et al. (2018). Minimal information for study of extracellular vesicles 2018 (MISEV2018): A position statement of the international society for extracellular vesicles and update of the MISEV2014 guidelines. J. Extracell Vesicles 7, 153570. doi:10.1080/20013078.2018.153570

Thorpe, C. T., Peffers, M. J., Simpson, D., Halliwell, E., Screen, H. R., and Clegg, P. D. (2016). Anatomical heterogeneity of tendon: Fascicular and inter fascicular
tendon compartments have distinct proteomic composition. Sci. Rep. 6, 20455. doi:10.1038/srep20455

Wang, B., Wang, Z. M., Ji, J. L., Gan, W., Zhang, A., Shi, H. J., et al. (2020a). Macrophage-derived exosomal mir-155 regulating cardiomyocyte pyroptosis and hypertrophy in septic cardiomyopathy. JACC. Basic Transl. Sci. 5, 148–166. doi:10.1016/j.jacbts.2019.10.011

Wang, H., Zhang, H., Sun, Q., Wang, Y., Yang, J., Yang, J., et al. (2017). Intra-articular delivery of antago-miR-483-5p inhibits osteoarthritis by modulating matrilin 3 and tissue inhibitor of metalloproteinase 2. Mol. Thor. 25, 715–727. doi:10.1016/j.ymthe.2016.12.020

Wang, Z., Wang, X., Zou, H., Dai, Z., Feng, S., Zhang, M., et al. (2020b). The basic characteristics of the pentraxin family and their functions in tumor progression. Front. Immunol. 11, 1757. doi:10.3389/fimmu.2020.01757

Wijesinghe, S. N., Badoume, A., Nanus, D. E., Davis, E. T., Lindsay, M. A., and Jones, S. W. (2020). Obese synovial fibroblasts exhibit single cell subsets with specific pathological inflammatory functions in osteoarthritis patients. Osteoarthr. Cartil. 28, S84. doi:10.1016/j.joca.2020.02.128

Wolf, E. J., Zhao, X., Hawn, S. E., Morrison, F. G., Zhou, Z., Fein-Schaffer, D., et al. (2021). Gene expression correlates of advanced epigenetic age and psychopathology in postmortem cortical tissue. Neurobiol. Stress 15, 100371. doi:10.1016/j.ynstr.2021.100371

Zerbino, D. R., Achten, P., Akanni, W., Amod, M. R., Barrell, D., Bhai, J., et al. (2018). Ensembl 2018. Nucleic Acids Res. 46, D754–D761. doi:10.1093/nar/gkx1099

Zhang, Y., Alexander, P. B., and Wang, X. F. (2017). TGF-Beta family signaling in the control of cell proliferation and survival. Cold Spring Harb. Perspect. Biol. 9, a022145. doi:10.1101/cshperspect.a022145

Zhang, Y., Liu, Y., Liu, H., and Tang, W. H. (2019). Exosomes: Biogenesis, biologic function and clinical potential. Cell Biosci. 9, 19. doi:10.1186/s13578-019-0282-2